Arno Therapeutics, Inc. HomeAbout UsPipelineInvestor RelationsContact Us
Creating the next generation of cancer treatments
Investor & Media
Press ReleasesIn the NewsPublicationsEvents & PresentationsStock Information
SEC FilingsAnnual ReportsGovernanceTransfer Agent

PRESS RELEASES



August 14, 2008

Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer

FAIRFIELD, N.J., Aug. 14, 2008 -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused on oncology, today announced the appointment of Brian Lenz, CPA, as its Chief Financial Officer. Mr. Lenz brings over 10 years of financial and operational management experience in addition to significant experience in capital raising and M&A activities.

"We are very pleased to have someone with Brian's broad financial and public markets experience join our team," said Scott Z. Fields, MD, President and Chief Medical Officer of Arno. "We look forward to working with him as we continue to grow and expand our operations."

Prior to joining Arno Therapeutics, Mr. Lenz was Chief Financial Officer and Treasurer of VioQuest Pharmaceuticals, Inc. since 2004, and prior to that served as the company's controller from 2003 to 2004. At VioQuest, Mr. Lenz was responsible for the financial and operational reporting, as well as capital raising and M&A activities. Prior to VioQuest, Mr. Lenz was a controller with Smiths Detection Group from 2000 to 2003. Before joining Smiths, Mr. Lenz was a senior auditor with KPMG, LLP from 1998 to 2000. Mr. Lenz holds a BS in Accounting from Rider University and received his MBA from Saint Joseph's University. He is a certified public accountant licensed in the State of New Jersey.

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead compound is AR-67, a novel, third-generation camptothecin analogue in Phase I studies in patients with advanced solid tumors that has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways also undergoing IND-enabling studies. Arno is actively pursuing additional compounds to expand its portfolio. For more information on Arno please visit www.arnothera.com.

Contact:
Brian Lenz, CPA
Chief Financial Officer
Arno Therapeutics, Inc.
(862) 703-7175
bl@arnothera.com

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Arno's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including those described under the caption "Risk Factors" in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2008. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.




Arno Therapeutics, Inc.
200 Route 31 North
Suite 104
Flemington, NJ 08822

(862) 703-7170 Main
(908) 237-0071 Fax

Email